These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15210644)

  • 1. Psoriasis and the new biologic agents: interrupting a T-AP dance.
    Walsh SR; Shear NH
    CMAJ; 2004 Jun; 170(13):1933-41. PubMed ID: 15210644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinantly engineered human proteins: transforming the treatment of psoriasis.
    Gottlieb AB; Bos JD
    Clin Immunol; 2002 Nov; 105(2):105-16. PubMed ID: 12482385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunobiologics in the treatment of psoriasis.
    Chong BF; Wong HK
    Clin Immunol; 2007 May; 123(2):129-38. PubMed ID: 17317321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologicals dramatic advances in the treatment of psoriasis.
    Wilsmann-Theis D; Martin S; Reber M; Kwiek B; Bieber T; Novak N
    Curr Pharm Des; 2006; 12(8):989-99. PubMed ID: 16533166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of moderate to severe plaque psoriasis with biologic therapy.
    Pariser DM
    Manag Care; 2003 Apr; 12(4):36-44. PubMed ID: 12747028
    [No Abstract]   [Full Text] [Related]  

  • 7. The immunologic basis for the treatment of psoriasis with new biologic agents.
    Krueger JG
    J Am Acad Dermatol; 2002 Jan; 46(1):1-23; quiz 23-6. PubMed ID: 11756941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapy for psoriasis: the new therapeutic frontier.
    Singri P; West DP; Gordon KB
    Arch Dermatol; 2002 May; 138(5):657-63. PubMed ID: 12020229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic agents in psoriasis.
    Lee MR; Cooper AJ
    Australas J Dermatol; 2006 Nov; 47(4):217-29; quiz 229-30. PubMed ID: 17034462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.
    Jullien D; Prinz JC; Langley RG; Caro I; Dummer W; Joshi A; Dedrick R; Natta P
    Dermatology; 2004; 208(4):297-306. PubMed ID: 15178911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
    Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
    Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel biological immunotherapies for psoriasis.
    Kanitakis J; Butnaru AC; Claudy A
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1111-21. PubMed ID: 12831347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-targeted biologicals for psoriasis.
    Griffiths CE
    Curr Drug Targets Inflamm Allergy; 2004 Jun; 3(2):157-61. PubMed ID: 15180468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
    Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
    J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bench to bedside--translational research in psoriasis.
    Prinz JC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():1-4. PubMed ID: 20831702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparing dermatology nurses: biologic therapy for psoriasis.
    Young MS
    Dermatol Nurs; 2003 Oct; 15(5):413-6, 419-23; quiz 424. PubMed ID: 14619318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.